BRCA1 and ovarian carcinoma: A recent preclinical study with an AXL-targeted ADC conjugated to a pyrrolobenzodiazepine cytotoxin showed potentially promising results in a BRCA1-mutated ovarian cancer model, highlighting the potential benefit of ADCs with varied mechanisms of action (38).